CAR-T with or without stem cell transplant for young women with myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 55 years old.
- You have been diagnosed with multiple myeloma.
- Your organs are working well enough, including your liver, kidneys, heart, and blood counts.
- You are in fairly good health, able to do daily activities without much help.
- If you could become pregnant, you must have a negative pregnancy test and use effective birth control for 24 months after treatment.
- You must not have had certain prior treatments, like other CAR-T therapies or a previous BCMA-targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This trial tests combining CAR-T cell therapy with a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to see if this approach can help when other treatments have failed.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.